A Phase 3 interventional study of Azilsartan medoxomil and Valsartan in Essential Hypertension, sponsored by Takeda. Completed at 30 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-03-05.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing azilsartan medoxomil in Essential Hypertension — none open to participants now, none under way, none of them phase 3. azilsartan medoxomil · Essential Hypertension.
Among the 11 studies testing azilsartan medoxomil in Essential Hypertension, this one is the 8th largest by enrollment, is one of 2 that started in 2015, is one of 10 in phase 3, and was the 10th registered.
480 studies on the registry are indexed under Essential Hypertension; 76 are open to participants now.
Browse Essential Hypertension studies →None of the 11 studies testing azilsartan medoxomil in Essential Hypertension is open now. The open studies under Essential Hypertension, anywhere →
azilsartan medoxomil: first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 45 Essential Hypertension studies recruiting now, 17 (38%) set no upper age limit and 20 (44%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 2 started in 2015.
This study's enrollment of 612 is above the median of 144 across 407 interventional studies indexed under Essential Hypertension.
Median enrollment 837 across the 11 interventional studies. Of the 11 that completed or were terminated, 11 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 11 have an industry lead sponsor. The 1 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
15 studies in Essential Hypertension by Takeda: none open now, none under way, none of them phase 3. Of 15 finished, 14 (93%) have results posted.
Among the 15 studies in Essential Hypertension by Takeda, this one is the 9th largest by enrollment, is one of 2 that started in 2015, is one of 12 in phase 3, and was the 14th registered.
Takeda’s Essential Hypertension studies by the year they started, since 2007.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing azilsartan medoxomil in Essential Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 15 in Essential Hypertension:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the antihypertensive effect of azilsartan medoxomil compared with valsartan in Chinese participants with essential hypertension.
The drug being tested in this study is called TAK-491 (azilsartan medoxomil). Azilsartan medoxomil is being tested to treat Chinese people who have essential hypertension. This study will look at change in blood pressure after 8 weeks of treatment in people who take azilsartan medoxomil compared to people who take valsartan.
The study enrolled 612 patients. Prior to the start of study treatment, participants who have not received antihypertensive treatment within 28 days participated in a 2-week -run in period. Upon completion of the run-in period, participants were randomly assigned (by chance, like flipping a coin) to one of the three treatment groups-which remain undisclosed to the patient and study doctor during the study (unless there is an urgent medical need):
All participants were asked to take study medication at the same time each day throughout the study.
This multi-centre trial was conducted in China. The overall time to participate in this study is up to 14 weeks. Participants made 9 visits to the clinic and contacted by telephone 14 days after last dose of study drug for a follow-up assessment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Is currently participating in another study or is receiving or has received any investigational compound within 30 days prior to the first dose of study medication.
Note: This criterion does not apply to participants who participated in observational studies that lacked an intervention or invasive procedure.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Run-in Period: azilsartan medoxomil 40 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets, and valsartan two 80 mg placebo-matching capsules, orally, once daily, for 2 weeks prior to the start of the treatment period. Treatment Period: azilsartan medoxomil 40 mg tablets, orally, once daily, azilsartan medoxomil 80 mg placebo-matching tablets, orally, once daily, and valsartan two 80 mg placebo-matching capsules, orally, once daily, for up to 8 weeks.
Drug: Azilsartan medoxomil · Drug: Azilsartan medoxomil Placebo · Drug: Valsartan Placebo
Run-in Period: azilsartan medoxomil 40 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets, and valsartan two 80 mg placebo-matching capsules, orally, once daily, for 2 weeks prior to the start of the treatment period. Treatment Period: azilsartan medoxomil 80 mg tablets, orally, once daily, azilsartan medoxomil 40 mg placebo-matching tablets, orally, once daily, and valsartan two 80 mg placebo-matching capsules, orally, once daily, for up to 8 weeks.
Drug: Azilsartan medoxomil · Drug: Azilsartan medoxomil Placebo · Drug: Valsartan Placebo
Run-in Period: azilsartan medoxomil 40 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets, and valsartan two 80 mg placebo-matching capsules, orally, once daily, for 2 weeks prior to the start of the treatment period. Treatment Period: valsartan two 80 mg capsules, orally, once daily, azilsartan medoxomil 40 mg placebo-matching tablets, orally, once daily, and azilsartan medoxomil 80 mg placebo-matching tablets, orally, once daily, for up to 8 weeks.
Drug: Valsartan · Drug: Azilsartan medoxomil Placebo · Drug: Valsartan Placebo
Azilsartan medoxomil tablets
Also known as: TAK-491, Edarbi
Valsartan 80 mg capsules
Also known as: Diovan®
Azilsartan medoxomil placebo-matching tablets
Valsartan placebo-matching capsules
Change From Baseline in Trough Sitting Clinic Systolic Blood Pressure (SBP)
The change in trough clinic sitting SBP measured at Week 8 relative to baseline. The trough is the average of the non-missing values of 3 serial trough sitting SBP measurements. Blood pressure was measured using a validated, automated device after the participant had been sitting for at least 5 minutes. Week 8 blood pressure was measured approximately 24 hours after the previous day's dose.
Time frame: Baseline and Week 8
Change From Baseline in Trough Sitting Clinic Diastolic Blood Pressure (DBP)
The change in trough clinic sitting DBP measured at Week 8 relative to baseline. The trough is the average of the non-missing values of 3 serial trough sitting DBP measurements. Blood pressure was measured using a validated, automated device after the participant had been sitting for at least 5 minutes. Week 8 blood pressure was measured approximately 24 hours after the previous day's dose.
Time frame: Baseline and Week 8
Percentage of Participants Who Achieved a Clinic SBP Response at Week 8
Clinic SBP response was defined as clinic SBP \<140 mm Hg and/or reduction of ≥20 mm Hg from Baseline. Blood pressure was measured using a validated, automated device after the participant had been sitting for at least 5 minutes. Week 8 blood pressure was measured approximately 24 hours after the previous day's dose.
Time frame: Week 8
Percentage of Participants Who Achieved a Clinic DBP Response at Week 8
Clinic DBP response was defined as clinic DBP \<90 mm Hg and/or reduction of ≥10 mm Hg from Baseline. Blood pressure was measured using a validated, automated device after the participant had been sitting for at least 5 minutes. Week 8 blood pressure was measured approximately 24 hours after the previous day's dose.
Time frame: Week 8
Percentage of Participants Who Achieved Both Clinic SBP and DBP Response at Week 8
Clinic SBP response was defined as clinic SBP \<140 mm Hg and/or reduction of ≥20 mm Hg from Baseline and clinic DBP response was defined as clinic DBP \<90 mm Hg and/or reduction of ≥10 mm Hg from Baseline. Blood pressure was measured using a validated, automated device after the participant had been sitting for at least 5 minutes. Week 8 blood pressure was measured approximately 24 hours after the previous day's dose.
Time frame: Week 8
Percentage of Participants Who Achieved Target Clinic SBP <140 mm Hg, Clinic DBP <90 mm Hg or Both at Week 8
Blood pressure was measured using a validated, automated device after the participant had been sitting for at least 5 minutes. Week 8 blood pressure was measured approximately 24 hours after the previous day's dose.
Time frame: Week 8
Percentage of Participants Who Achieved Target Clinic SBP <130 mm Hg, Target Clinic DBP <80 mm Hg or Both at Week 8
Blood pressure was measured using a validated, automated device after the participant had been sitting for at least 5 minutes. Week 8 blood pressure was measured approximately 24 hours after the previous day's dose.
Time frame: Week 8
Participants took part in the study at 30 investigative sites in China from 27 August 2015 to 13 October 2017.
| Milestone | Azilsartan Medoxomil 40 mg | Azilsartan Medoxomil 80 mg | Valsartan 160 mg |
|---|---|---|---|
| Started | 199 | 209 | 204 |
| Completed | 189 | 189 | 183 |
| Not completed | 10 | 20 | 21 |
| Withdrew: Pretreatment event/adverse event | 3 | 6 | 3 |
| Withdrew: Major protocol deviation | 1 | 4 | 3 |
| Withdrew: Lost to follow-up | 0 | 1 | 2 |
| Withdrew: Voluntary withdrawal | 6 | 5 | 10 |
| Withdrew: Lack of efficacy | 0 | 3 | 3 |
| Withdrew: Reason not specified | 0 | 1 | 0 |
The change in trough clinic sitting SBP measured at Week 8 relative to baseline. The trough is the average of the non-missing values of 3 serial trough sitting SBP measurements. Blood pressure was measured using a validated, automated device after the participant had been sitting for at least 5 minutes. Week 8 blood pressure was measured approximately 24 hours after the previous day's dose.
| mm Hg | Azilsartan Medoxomil 40 mg | Azilsartan Medoxomil 80 mg | Valsartan 160 mg |
|---|---|---|---|
| Baseline SBP | 157.873 ± 0.5123 | 158.236 ± 0.5010 | 158.594 ± 0.5123 |
| Change at Week 8 | -22.483 ± 1.0258 | -24.236 ± 1.0027 | -20.551 ± 1.0258 |
The change in trough clinic sitting DBP measured at Week 8 relative to baseline. The trough is the average of the non-missing values of 3 serial trough sitting DBP measurements. Blood pressure was measured using a validated, automated device after the participant had been sitting for at least 5 minutes. Week 8 blood pressure was measured approximately 24 hours after the previous day's dose.
| mm Hg | Azilsartan Medoxomil 40 mg | Azilsartan Medoxomil 80 mg | Valsartan 160 mg |
|---|---|---|---|
| Baseline DBP | 91.790 ± 0.7306 | 91.510 ± 0.7145 | 92.298 ± 0.7306 |
| Change at Week 8 | -10.101 ± 0.6684 | -11.463 ± 0.6538 | -8.641 ± 0.6686 |
Clinic SBP response was defined as clinic SBP \<140 mm Hg and/or reduction of ≥20 mm Hg from Baseline. Blood pressure was measured using a validated, automated device after the participant had been sitting for at least 5 minutes. Week 8 blood pressure was measured approximately 24 hours after the previous day's dose.
| percentage of participants | Azilsartan Medoxomil 40 mg | Azilsartan Medoxomil 80 mg | Valsartan 160 mg |
|---|---|---|---|
| Percentage of Participants Who Achieved a Clinic SBP Response at Week 8 | 67.0 | 68.9 | 69.0 |
Clinic DBP response was defined as clinic DBP \<90 mm Hg and/or reduction of ≥10 mm Hg from Baseline. Blood pressure was measured using a validated, automated device after the participant had been sitting for at least 5 minutes. Week 8 blood pressure was measured approximately 24 hours after the previous day's dose.
| percentage of participants | Azilsartan Medoxomil 40 mg | Azilsartan Medoxomil 80 mg | Valsartan 160 mg |
|---|---|---|---|
| Percentage of Participants Who Achieved a Clinic DBP Response at Week 8 | 81.2 | 81.6 | 79.7 |
Clinic SBP response was defined as clinic SBP \<140 mm Hg and/or reduction of ≥20 mm Hg from Baseline and clinic DBP response was defined as clinic DBP \<90 mm Hg and/or reduction of ≥10 mm Hg from Baseline. Blood pressure was measured using a validated, automated device after the participant had been sitting for at least 5 minutes. Week 8 blood pressure was measured approximately 24 hours after the previous day's dose.
| percentage of participants | Azilsartan Medoxomil 40 mg | Azilsartan Medoxomil 80 mg | Valsartan 160 mg |
|---|---|---|---|
| Percentage of Participants Who Achieved Both Clinic SBP and DBP Response at Week 8 | 62.9 | 67.0 | 64.5 |
Blood pressure was measured using a validated, automated device after the participant had been sitting for at least 5 minutes. Week 8 blood pressure was measured approximately 24 hours after the previous day's dose.
| percentage of participants | Azilsartan Medoxomil 40 mg | Azilsartan Medoxomil 80 mg | Valsartan 160 mg |
|---|---|---|---|
| Clinic SBP <140 mm Hg | 60.9 | 62.6 | 62.9 |
| Clinic DBP <90 mm Hg | 77.2 | 76.7 | 74.6 |
| Clinic SBP <140 mm Hg and DBP <90 mm Hg | 58.4 | 60.2 | 55.8 |
Blood pressure was measured using a validated, automated device after the participant had been sitting for at least 5 minutes. Week 8 blood pressure was measured approximately 24 hours after the previous day's dose.
| percentage of participants | Azilsartan Medoxomil 40 mg | Azilsartan Medoxomil 80 mg | Valsartan 160 mg |
|---|---|---|---|
| Clinic SBP <130 mm Hg | 37.6 | 42.7 | 28.4 |
| Clinic DBP <80 mm Hg | 45.2 | 51.9 | 37.1 |
| Clinic SBP <130 mm Hg and DBP <80 mm Hg | 28.9 | 33.0 | 21.8 |
Collected over From first dose of study drug through 14 days after the last dose of study drug (Up to Week 12). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Azilsartan Medoxomil 40 mg | 1/199 (0.5%) | 2/199 (1%) | 34/199 (17.1%) |
| Azilsartan Medoxomil 80 mg | 0/209 (0%) | 7/209 (3.3%) | 37/209 (17.7%) |
| Valsartan 160 mg | 0/204 (0%) | 6/204 (2.9%) | 35/204 (17.2%) |
| Event | Azilsartan Medoxomil 40 mg | Azilsartan Medoxomil 80 mg | Valsartan 160 mg |
|---|---|---|---|
| Subarachnoid haemorrhageInjury, poisoning and procedural complications | 1/199 | 0/209 | 0/204 |
| HypertensionVascular disorders | 1/199 | 1/209 | 1/204 |
| PneumoniaInfections and infestations | 0/199 | 0/209 | 1/204 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 0/199 | 0/209 | 1/204 |
| Lacunar infarctionNervous system disorders | 0/199 | 1/209 | 1/204 |
| Cerebrovascular insufficiencyNervous system disorders | 0/199 | 0/209 | 1/204 |
| Urate nephropathyRenal and urinary disorders | 0/199 | 0/209 | 1/204 |
| Peptic ulcer haemorrhageGastrointestinal disorders | 0/199 | 1/209 | 0/204 |
| Meniscus injuryInjury, poisoning and procedural complications | 0/199 | 1/209 | 0/204 |
| Ovarian neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/199 | 1/209 | 0/204 |
| Event | Azilsartan Medoxomil 40 mg | Azilsartan Medoxomil 80 mg | Valsartan 160 mg |
|---|---|---|---|
| HyperlipidaemiaMetabolism and nutrition disorders | 14/199 | 14/209 | 16/204 |
| Upper respiratory tract infectionInfections and infestations | 10/199 | 13/209 | 14/204 |
| AlbuminuriaRenal and urinary disorders | 11/199 | 10/209 | 6/204 |
| HyperuricaemiaMetabolism and nutrition disorders | 8/199 | 11/209 | 8/204 |
Safety Analysis Set included all participants who received at least 1 dose of double-blind study drug.
| Age, Continuous(years) | Azilsartan Medoxomil 40 mg | Azilsartan Medoxomil 80 mg | Valsartan 160 mg | Total |
|---|---|---|---|---|
| Mean | 57.4 ± 9.52 | 57.0 ± 9.88 | 56.8 ± 9.48 | 57.1 ± 9.62 |
| Sex: Female, Male(Participants) | Azilsartan Medoxomil 40 mg | Azilsartan Medoxomil 80 mg | Valsartan 160 mg | Total |
|---|---|---|---|---|
| Female | 92 | 94 | 74 | 260 |
| Male | 107 | 115 | 130 | 352 |
| Race/Ethnicity, Customized(Participants) | Azilsartan Medoxomil 40 mg | Azilsartan Medoxomil 80 mg | Valsartan 160 mg | Total |
|---|---|---|---|---|
| Asian | 199 | 209 | 204 | 612 |
| Region of Enrollment(Participants) | Azilsartan Medoxomil 40 mg | Azilsartan Medoxomil 80 mg | Valsartan 160 mg | Total |
|---|---|---|---|---|
| China | 199 | 209 | 204 | 612 |
| Height(cm) | Azilsartan Medoxomil 40 mg | Azilsartan Medoxomil 80 mg | Valsartan 160 mg | Total |
|---|---|---|---|---|
| Mean | 164.3 ± 8.92 | 164.2 ± 8.81 | 165.3 ± 7.73 | 164.6 ± 8.50 |
| Weight(kg) | Azilsartan Medoxomil 40 mg | Azilsartan Medoxomil 80 mg | Valsartan 160 mg | Total |
|---|---|---|---|---|
| Mean | 71.75 ± 14.046 | 71.60 ± 11.903 | 72.79 ± 12.903 | 72.05 ± 12.952 |
| Body Mass Index (BMI)(kg/m^2) | Azilsartan Medoxomil 40 mg | Azilsartan Medoxomil 80 mg | Valsartan 160 mg | Total |
|---|---|---|---|---|
| Mean | 26.43 ± 3.784 | 26.47 ± 3.436 | 26.52 ± 3.444 | 26.48 ± 3.550 |
| Smoking Classification(Participants) | Azilsartan Medoxomil 40 mg | Azilsartan Medoxomil 80 mg | Valsartan 160 mg | Total |
|---|---|---|---|---|
| Participant has never smoked | 151 | 147 | 136 | 434 |
| Participant is a current smoker | 39 | 51 | 55 | 145 |
| Participant is an ex-smoker | 9 | 11 | 13 | 33 |
3 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda makes patient-level, de-identified data sets and associated documents available after applicable marketing approvals and commercial availability have been received, an opportunity for the primary publication of the research has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com/Approach for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.
Ran from Aug 2015 to primary completion in Sep 2017, 24 months.
Results were first posted in Feb 2019, 1 year 4 months after primary completion.
Of 45 industry-sponsored phase 3 interventional studies under Essential Hypertension, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 24. This study's 24 months is above that.
Counting every sponsor, half of 47 studies reached it within 17 months; a quarter within 11 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Azilsartan medoxomil